ALKERMES PLCG01767105IE00B56GVS1505/20/2026To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER17134330FOR1713433FOR ALNYLAM PHARMACEUTICALS, INC.02043Q107US02043Q107605/20/2026To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER61960FOR6196FOR ANI PHARMACEUTICALS, INC.00182C103US00182C103605/21/2026To approve the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER3116760FOR311676FOR ANI PHARMACEUTICALS, INC.00182C103US00182C103605/21/2026To approve the frequency of future advisory votes to approve the compensation of the Company's named executive officers, on a non-binding basis.SECTION 14A SAY-ON-PAY VOTESISSUER31167601 YEAR311676FOR ARCUS BIOSCIENCES, INC.03969F109US03969F109306/11/2026To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1067800FOR106780FOR ARGENX SE04016X101US04016X101905/06/2026The 2025 remuneration report (advisory non-binding voting item)SECTION 14A SAY-ON-PAY VOTESISSUER266480FOR26648FOR AXOGEN, INC.05463X106US05463X106306/23/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER4326690FOR432669FOR BIODESIX, INC.09075X207US09075X207105/19/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER4297270FOR429727FOR BIODESIX, INC.09075X207US09075X207105/19/2026To approve, on a non-binding advisory basis, the frequency of solicitation of advisory votes to approve named executive officer compensation;SECTION 14A SAY-ON-PAY VOTESISSUER42972701 YEAR429727FOR BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER6495640FOR649564FOR C4 THERAPEUTICS, INC.12529R107US12529R107706/24/2026To cast a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER38039420FOR3803942FOR CAPRICOR THERAPEUTICS, INC.14070B309US14070B309606/04/2026APPROVAL OF A NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASISSECTION 14A SAY-ON-PAY VOTESISSUER12430FOR1243FOR CAPRICOR THERAPEUTICS, INC.14070B309US14070B309606/04/2026APPROVAL OF FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASISSECTION 14A SAY-ON-PAY VOTESISSUER124301 YEAR1243FOR CELCUITY INC.15102K100US15102K100705/14/2026To approve, on an advisory basis, named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER12579940FOR1257994FOR CERUS CORPORATION157085101US157085101406/02/2026Advisory Votes on Executive Compensation - The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER87605340FOR8760534FOR CG ONCOLOGY, INC.156944100US156944100906/04/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER9080FOR908FOR CG ONCOLOGY, INC.156944100US156944100906/04/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER90801 YEAR908FOR COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER100000FOR10000FOR CORCEPT THERAPEUTICS INCORPORATED218352102US218352102805/21/2026To approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER533320FOR53332FOR CULLINAN THERAPEUTICS, INC.230031106US230031106306/16/2026Proposal to vote, on an advisory basis, to approve our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1050730FOR105073FOR CYTOMX THERAPEUTICS, INC.23284F105US23284F105706/17/2026To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; andSECTION 14A SAY-ON-PAY VOTESISSUER5940FOR594FOR CYTOMX THERAPEUTICS, INC.23284F105US23284F105706/17/2026To hold a non-binding advisory vote on the frequency of future advisory votes by stockholders on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER59401 YEAR594FOR DEXCOM, INC.252131107US252131107405/27/2026To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER202070FOR20207FOR EDAP TMS S.A.268311107US268311107206/26/2026Non-binding advisory vote to approve the compensation for named executive officers of the Company;SECTION 14A SAY-ON-PAY VOTESISSUER73092540FOR7309254FOR EDAP TMS S.A.268311107US268311107206/26/2026Non-binding advisory vote to hold a non-binding advisory vote on the compensation for the named executive officers of the Company every year;SECTION 14A SAY-ON-PAY VOTESISSUER73092540FOR7309254FOR EDAP TMS S.A.268311107US268311107206/26/2026Non-binding advisory vote to hold a non-binding advisory vote on the compensation for the named executive officers of the Company every two years;SECTION 14A SAY-ON-PAY VOTESISSUER73092540FOR7309254AGAINST EDAP TMS S.A.268311107US268311107206/26/2026Non-binding advisory vote to hold a non-binding advisory vote on the compensation for the named executive officers of the Company every three years;SECTION 14A SAY-ON-PAY VOTESISSUER73092540FOR7309254AGAINST EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER14299150FOR1429915FOR ENLIVEN THERAPEUTICS, INC.29337E102US29337E102906/09/2026To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in our proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER108690FOR10869FOR ENLIVEN THERAPEUTICS, INC.29337E102US29337E102906/09/2026To approve, in an advisory (non-binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1086901 YEAR10869FOR ESSA PHARMA INC.29668H708CA29668H708510/03/2025Compensation Resolution- To consider, and, if thought advisable, to pass, an ordinary resolution to approve, on an advisory and non-binding basis, the compensation to be paid or become payable to its named executive officers that is based on or otherwise relates to the Arrangement, all as more particularly described in the Circular and Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER43057630FOR4305763FOR EVOLUS, INC.30052C107US30052C107106/11/2026Approval of, on an advisory basis, the compensation of Evolus' named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER22453600FOR2245360FOR GENEDX HOLDINGS CORP.81663L200US81663L200706/18/2026Approval, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER388030FOR38803FOR GENEDX HOLDINGS CORP.81663L200US81663L200706/18/2026Indicate, on a non-binding advisory basis, whether future advisory votes on the compensation paid by us to our named executive officers should be held every one, two, or three years.SECTION 14A SAY-ON-PAY VOTESISSUER3880301 YEAR38803FOR GERON CORPORATION374163103US374163103605/20/2026To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in our Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER415086590FOR41508659FOR GLOBUS MEDICAL, INC.379577208US379577208206/03/2026Approval, on a non-binding, advisory basis, of the 2025 compensation of the company's named executive officers (the "Say-on-Pay" Vote).SECTION 14A SAY-ON-PAY VOTESISSUER2185130FOR218513FOR INDIVIOR PHARMACEUTICALS, INC.45579U109US45579U109705/13/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER6560590FOR656059FOR INDIVIOR PHARMACEUTICALS, INC.45579U109US45579U109705/13/2026To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER65605901 YEAR656059FOR INHIBIKASE THERAPEUTICS, INC.45719W205US45719W205206/26/2026to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER93832490FOR9383249FOR INHIBIKASE THERAPEUTICS, INC.45719W205US45719W205206/26/2026to vote, on a non-binding, advisory basis, on the frequency of future non-binding, advisory votes on compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER938324901 YEAR9383249FOR INSMED INCORPORATED457669307US457669307505/13/2026An advisory vote on the 2025 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER530FOR53FOR INSPIRE MEDICAL SYSTEMS, INC.457730109US457730109004/30/2026Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1909040FOR190904FOR INSPIRE MEDICAL SYSTEMS, INC.457730109US457730109004/30/2026Approval, on an advisory (non-binding) basis, of the frequency of future advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER19090401 YEAR190904FOR INSULET CORPORATION45784P101US45784P101205/20/2026To approve, on a non-binding, advisory basis, the compensation of certain executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1304980FOR130498FOR IOVANCE BIOTHERAPEUTICS, INC.462260100US462260100706/10/2026To approve, by non-binding advisory vote, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER376620FOR37662FOR IOVANCE BIOTHERAPEUTICS, INC.462260100US462260100706/10/2026To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER3766201 YEAR37662FOR JASPER THERAPEUTICS INC.471871202US471871202307/03/2025Advisory vote on approval of the compensation of the named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER11214310FOR1121431FOR JASPER THERAPEUTICS INC.471871202US471871202307/03/2025Advisory vote on the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER112143101 YEAR1121431FOR KARYOPHARM THERAPEUTICS INC.48576U205US48576U205005/21/2026To approve, on an advisory basis, the compensation of our named executive officers, as described in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1216560FOR121656FOR KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026To approve, on an advisory (non-binding) basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER4592120FOR459212FOR KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0705/29/2026To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4592120FOR459212FOR KODIAK SCIENCES INC.50015M109US50015M109906/02/2026Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER70FOR7FOR KRYSTAL BIOTECH, INC.501147102US501147102705/15/2026Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER2010010FOR201001FOR LARIMAR THERAPEUTICS, INC.517125100US517125100305/19/2026Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER8884070FOR888407FOR LARIMAR THERAPEUTICS, INC.517125100US517125100305/19/2026Approval, on an Advisory Basis, of the Preferred Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER88840701 YEAR888407FOR LIQUIDIA CORPORATION53635D202US53635D202706/16/2026To approve, on an non-binding basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2310FOR231FOR LIVANOVA PLCG5509L101GB00BYMT0J1906/10/2026Ordinary Resolution: To approve, on an advisory basis, the Company's compensation of its named executive officers ("U.S. Say on Pay").SECTION 14A SAY-ON-PAY VOTESISSUER5353080FOR535308FOR MERCK & CO., INC.58933Y105US58933Y105505/26/2026Non-binding advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER399900FOR39990FOR MIRUM PHARMACEUTICALS, INC.604749101US604749101306/15/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER724920FOR72492FOR NATERA, INC.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER356020FOR35602FOR NATERA, INC.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3560201 YEAR35602FOR NEOGENOMICS, INC.64049M209US64049M209805/21/2026Approval, on a non-binding advisory basis, of the Compensation Paid to the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER1720830FOR172083FOR NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026Advisory vote on the compensation paid to the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER2080FOR208FOR NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/03/2026A non-binding advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER75852090FOR7585209FOR NURIX THERAPEUTICS, INC.67080M103US67080M103605/15/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER818010FOR81801FOR ORGANOGENESIS HOLDINGS INC68621F102US68621F102106/15/2026Approval, on an advisory basis, of the compensation paid to our named executive officers, as disclosed in the Company's proxy statement for its 2026 annual meeting of shareholders.SECTION 14A SAY-ON-PAY VOTESISSUER100859510FOR10085951FOR ORTHOPEDIATRICS CORP.68752L100US68752L100806/04/2026To approve, on an advisory basis, the compensation of our executive officers who are named in the compensation disclosures in this proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER6154470FOR615447FOR ORUKA THERAPEUTICS, INC.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER10230FOR1023FOR PRAXIS PRECISION MEDICINES, INC.74006W207US74006W207006/10/2026To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTESISSUER3319810FOR331981FOR PROCEPT BIOROBOTICS CORPORATION74276L105US74276L105206/09/2026Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER206030FOR20603FOR PROGYNY, INC.74340E103US74340E103805/21/2026Approval, on an advisory (non-binding) basis, of the compensation of the company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER9364570FOR936457FOR PULMONX CORPORATION745848101US745848101406/04/2026To conduct a non-binding advisory vote to approve our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER27883230FOR2788323FOR RIGEL PHARMACEUTICALS, INC.766559702US766559702405/14/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER2680FOR268FOR STAAR SURGICAL COMPANY852312305US852312305201/06/2026A proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to STAAR's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement.SECTION 14A SAY-ON-PAY VOTESISSUER1963320FOR196332FOR STAAR SURGICAL COMPANY852312305US852312305206/18/2026Approve on a non-binding advisory basis the compensation of the Company's named executive officers ("say-on-pay").SECTION 14A SAY-ON-PAY VOTESISSUER25970FOR2597FOR STRUCTURE THERAPEUTICS, INC.86366E106US86366E106406/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER851220FOR85122FOR SUPERNUS PHARMACEUTICALS, INC.868459108US868459108906/18/2026To approve, on a non-binding basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1112210FOR111221FOR SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER3262930FOR326293FOR TANDEM DIABETES CARE, INC.875372203US875372203705/20/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1577000FOR157700FOR TANGO THERAPEUTICS, INC.87583X109US87583X109006/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER990940FOR99094FOR TECTONIC THERAPEUTIC, INC878972108US878972108606/08/2026Advisory approval of the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER282680FOR28268FOR TELEFLEX INCORPORATED879369106US879369106905/15/2026Approval, on an advisory basis, of named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2020FOR202FOR TENET HEALTHCARE CORPORATION88033G407US88033G407305/27/2026To approve, on an advisory basis, the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER5240FOR524FOR TG THERAPEUTICS, INC.88322Q108US88322Q108506/11/2026An advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2317720FOR231772FOR TRAVERE THERAPEUTICS, INC.89422G107US89422G107605/19/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1110510FOR111051FOR TRAVERE THERAPEUTICS, INC.89422G107US89422G107605/19/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER11105101 YEAR111051FOR TREVI THERAPEUTICS INC89532M101US89532M101806/03/2026Approval, on an advisory basis, of the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3120840FOR312084FOR TWIST BIOSCIENCE CORPORATION90184D100US90184D100002/05/2026To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named Executive Officers, as described in the Proxy Statement under ''Executive Compensation.''SECTION 14A SAY-ON-PAY VOTESISSUER3980640FOR398064FOR UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1878430FOR187843FOR UROGEN PHARMA LTDM96088105IL001140714008/26/2025To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER18850000FOR1885000FOR UROGEN PHARMA LTDM96088105IL001140714008/26/2025To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER188500001 YEAR1885000FOR UROGEN PHARMA LTDM96088105IL001140714006/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER4470000FOR447000FOR VAXCYTE, INC.92243G108US92243G108506/15/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER579160FOR57916FOR VERACYTE, INC.92337F107US92337F107506/10/2026The approval, on a non-binding advisory basis, of the compensation of our named executive officers, as disclosed in our proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER693300FOR69330FOR VERICEL CORPORATION92346J108US92346J108804/29/2026To approve, on an advisory basis, the compensation of Vericel Corporation's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER8640370FOR864037FOR VIR BIOTECHNOLOGY, INC.92764N102US92764N102805/26/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER20020000FOR2002000FOR XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER2919340FOR291934FOR XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER29193401 YEAR291934FOR Y-MABS THERAPEUTICS, INC.984241109US984241109507/11/2025To approve, on a non-binding advisory vote basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER3236180FOR323618FOR ZENTALIS PHARMACEUTICALS, INC.98943L107US98943L107006/16/2026Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3025190FOR302519FOR